U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C13H18Cl2N2O2.ClH
Molecular Weight 341.661
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Melphalan hydrochloride

SMILES

Cl.N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O

InChI

InChIKey=OUUYBRCCFUEMLH-YDALLXLXSA-N
InChI=1S/C13H18Cl2N2O2.ClH/c14-5-7-17(8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19;/h1-4,12H,5-9,16H2,(H,18,19);1H/t12-;/m0./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C13H18Cl2N2O2
Molecular Weight 305.2
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Melphalan, also known as L-phenylalanine mustard, phenylalanine mustard, L-PAM, or L-sarcolysin, is a phenylalanine derivative of nitrogen mustard. Melphalan is a bifunctional alkylating agent which produces a number of DNA adducts with the DNA interstrand crosslink (ICL) considered to be the critical cytotoxic lesion. Melphalan is used to treat different cancers including myeloma, melanoma and ovarian cancer.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
0.078 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
ALKERAN
Palliative
ALKERAN
Primary

Cmax

ValueDoseCo-administeredAnalytePopulation
432 ng/mL
40 mg single, intravenous
MELPHALAN plasma
Homo sapiens
419 ng/mL
40 mg 1 times / 4 weeks steady-state, intravenous
MELPHALAN plasma
Homo sapiens
580 ng/mL
40 mg single, intravenous
MELPHALAN plasma
Homo sapiens
580 ng/mL
40 mg single, intravenous
MELPHALAN plasma
Homo sapiens
516 ng/mL
40 mg single, intravenous
MELPHALAN plasma
Homo sapiens
503 ng/mL
40 mg single, intravenous
MELPHALAN plasma
Homo sapiens
161 ng/mL
40 mg single, intravenous
MELPHALAN FLUFENAMIDE plasma
Homo sapiens
87 ng/mL
40 mg single, intravenous
MELPHALAN FLUFENAMIDE plasma
Homo sapiens
433 ng/mL
40 mg single, intravenous
MELPHALAN plasma
Homo sapiens
429 ng/mL
40 mg single, intravenous
MELPHALAN plasma
Homo sapiens
212 ng/mL
14 mg single, oral
MELPHALAN plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
3143 ng × h/mL
40 mg single, intravenous
MELPHALAN plasma
Homo sapiens
2933 ng × h/mL
40 mg 1 times / 4 weeks steady-state, intravenous
MELPHALAN plasma
Homo sapiens
8233 ng × h/mL
40 mg single, intravenous
MELPHALAN plasma
Homo sapiens
8233 ng × h/mL
40 mg single, intravenous
MELPHALAN plasma
Homo sapiens
62222 ng × h/mL
40 mg single, intravenous
MELPHALAN plasma
Homo sapiens
72466 ng × h/mL
40 mg single, intravenous
MELPHALAN plasma
Homo sapiens
3839 ng × h/mL
40 mg single, intravenous
MELPHALAN FLUFENAMIDE plasma
Homo sapiens
1872 ng × h/mL
40 mg single, intravenous
MELPHALAN FLUFENAMIDE plasma
Homo sapiens
52192 ng × h/mL
40 mg single, intravenous
MELPHALAN plasma
Homo sapiens
53938 ng × h/mL
40 mg single, intravenous
MELPHALAN plasma
Homo sapiens
498 ng × h/mL
14 mg single, oral
MELPHALAN plasma
Homo sapiens
12.84 mg × h/L
200 mg/m² single, intravenous
MELPHALAN plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
2.1 min
single, intravenous
MELPHALAN FLUFENAMIDE plasma
Homo sapiens
70 min
single, intravenous
MELPHALAN plasma
Homo sapiens
80 min
40 mg single, intravenous
MELPHALAN plasma
Homo sapiens
80 min
40 mg single, intravenous
MELPHALAN plasma
Homo sapiens
1 h
14 mg single, oral
MELPHALAN plasma
Homo sapiens
75 min
100 mg/m² 1 times / day multiple, intravenous
MELPHALAN plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
70%
100 mg/m² 1 times / day multiple, intravenous
MELPHALAN plasma
Homo sapiens

Doses

AEs

Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Sample Use Guides

In Vivo Use Guide
Relapsed or refractory multiple myeloma: recommended dosage of PEPAXTO is 40 mg intravenously over 30 minutes on Day 1 of each 28-day treatment cycle, in combination with dexamethasone.
Route of Administration: Intravenous
In Vitro Use Guide
Melflufen showed activity with cytotoxic IC50-values in the submicromolar range (0.011-0.92 uM) in the cell lines. In the primary cultures melflufen yielded slightly lower IC50-values (2.7 nM to 0.55 uM). Treated cell lines exhibited a clear accumulation in the G2/M-phase of the cell cycle.
Substance Class Chemical
Record UNII
1VXP4V453T
Record Status Validated (UNII)
Record Version